News | May 28, 2021
Remdesivir demand was exaggerated: Dr. Sharvil Patel
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
This marks Glenmark's first synthetic decapeptide injectable approval
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Subscribe To Our Newsletter & Stay Updated
